Skip to main content

Table 2 The average dosimetric characteristic for the fourteen patients

From: Improve the dosimetric outcome in bilateral head and neck cancer (HNC) treatment using spot-scanning proton arc (SPArc) therapy: a feasibility study

Structure

Value

SPArc

IMPT

pValue

CTV_high

D95(Gy) [RBE]

70.8 ± 0.2

70.7 ± 0.2

0.975

 

D5(Gy) [RBE]

73.6 ± 0.8

74.1 ± 0.7

0.011

 

HI

1.04 ± 0.01

1.05 ± 0.01

0.005

 

CI

0.70 ± 0.06

0.67 ± 0.07

0.006

CTV_low

D95(Gy) [RBE]

60.8 ± 0.4

60.8 ± 0.4

0.777

 

D5(Gy) [RBE]

64.6 ± 1.0

65.7 ± 1.7

0.003

 

HI

1.07 ± 0.04

1.09 ± 0.05

0.003

 

CI

0.54 ± 0.09

0.51 ± 0.10

0.017

Cord

D1(Gy) [RBE]

17.2 ± 7.0

21.7 ± 7.9

0.009

Brain Stem

D1(Gy) [RBE]

14.2 ± 11.1

15.9 ± 11.3

0.048

Contralateral Parotid

Mean Dose (Gy) [RBE]

17.9 ± 6.4

22.6 ± 5.3

0.001

Ipsilateral Parotid

Mean Dose (Gy) [RBE]

21.1 ± 7.4

28.4 ± 6.2

0.001

Oral Cavity

Mean Dose (Gy) [RBE]

21.9 ± 9.7

27.5 ± 9.4

0.001

External

ID (Gy · L)

121.8 ± 29.7

147.0 ± 33.8

0.001

V1Gy

cc

6186.9 ± 1800.1

5852.7 ± 1543.5

0.011

V3Gy

cc

4710.8 ± 1328.4

5137.8 ± 1331.7

0.008

  1. Abbreviations: HI (homogeneity index), RBE relative biological effectiveness, Dx the maximum dose covering x% volume of a structure, ID the integral dose, Vx the volume of a structure received x Gy [RBE]